Stem Cell Therapy / Regenerative Medicine / SVF Injection
A regenerative medicine approach where a patient's own fat tissue (adipose) is harvested via mini-liposuction, processed to isolate the stromal vascular fraction (SVF) containing mesenchymal stem cells and growth factors, then reinjected at target sites — combining autologous (self-derived) stem cells with targeted delivery.
How it works
Adipose tissue is harvested under local anaesthesia and processed (enzymatic digestion or mechanical disruption) to isolate the SVF — a heterogeneous cell mixture containing adipose-derived stem cells (ADSCs), pericytes, endothelial progenitor cells, and macrophages. ADSCs are multipotent mesenchymal stem cells that secrete paracrine factors (growth factors, cytokines) that modulate inflammation, stimulate angiogenesis, and support tissue regeneration. Cells may also differentiate into target tissue types.
Reported benefits
- Joint regeneration in osteoarthritis (knee, hip, shoulder)
- Orthopedic injury recovery acceleration
- Skin rejuvenation when combined with microneedling or PRP
- Hair restoration (ADSC + PRP hair protocol)
- Anti-aging and longevity support
- Potential neuroprotective applications (investigational)
Regulatory status
Approved for: Advanced Therapy Medicinal Products (ATMPs) — approved through centralised EMA procedure, Orthopedic and wound healing applications in some countries
EMA regulates stem cell therapies as Advanced Therapy Medicinal Products (ATMPs) — the most regulated category. Chondrocelect (cartilage) and Holoclar (cornea) are approved ATMPs. Commercial wellness ADSC is not EMA-approved. Hospital exemptions allow some clinical ADSC use. Significant regulatory variation between EU countries.
Approved for: Licensed Advanced Therapy Medicinal Products only
MHRA regulates stem cell therapies as ATMPs. Post-Brexit, UK has its own ATMP approval pathway. MHRA has issued warnings about unlicensed stem cell clinics. Legitimate use limited to clinical trials and licensed products. Significant enforcement activity against illegal stem cell tourism.
Approved for: Haematopoietic stem cell transplants (bone marrow) — approved, Adipose-derived stem cells for orthopedic use — some cleared, Cosmetic ADSC use — not approved, under increased FDA scrutiny
FDA issued guidance in 2017 clarifying that most stem cell therapies (including adipose-derived) are subject to full drug approval requirements unless meeting very narrow same-day surgical procedure exceptions. FDA has taken enforcement action against many stem cell clinics. Legitimate clinical trials exist; commercial cosmetic/wellness ADSC is legally grey in the US.
Practical details
Frequency: Single procedure; repeat after 12–24 months if needed
Results last: Harvesting + processing + injection in one day; anti-inflammatory effects within weeks; full tissue remodelling at 3–6 months
Contraindications:
- Active cancer or cancer history (stem cells may stimulate tumour growth)
- Active systemic infection or sepsis
- Blood disorders
- Pregnancy
- Patients on immunosuppressive therapy
- Regulatory restrictions vary significantly by country — only legally available at licensed clinics
Always consult a licensed medical professional before undergoing any treatment. This information is educational only and does not constitute medical advice.